Rhinocerebral Mucormycosis as a Sequelae of COVID-19 Treatment: A Case Report & Literature Review

Andrew J Deek; Stefanos Boukovalas; Christopher J Rathfoot; Jack E Gotcher

doi:10.1016/j.joms.2021.09.009

Rhinocerebral Mucormycosis as a Sequelae of COVID-19 Treatment: A Case Report & Literature Review

J Oral Maxillofac Surg. 2022 Feb;80(2):333-340. doi: 10.1016/j.joms.2021.09.009. Epub 2021 Sep 20.

Authors

Andrew J Deek¹, Stefanos Boukovalas², Christopher J Rathfoot³, Jack E Gotcher⁴

Affiliations

¹ Resident physician, Department of Oral & Maxillofacial Surgery, University of Tennessee Medical Center in Knoxville, Knoxville, TN. Electronic address: ADeek@utmck.edu.
² Assistant Professor, Department of Plastic & Reconstructive Surgery, University of Tennessee Medical Center in Knoxville, Knoxville, TN.
³ Attending Physician, Department of Otolaryngology, Knoxville, TN.
⁴ Program director, Department of Oral & Maxillofacial Surgery, University of Tennessee Medical Center in Knoxville, Knoxville, TN.

Abstract

A large volume of reports detailing a marked increase in Mucormycosis infections in India has filtered its way into world news articles. These patients frequently have 2 risk factors: recent treatment of COVID-19 with high dose steroids, and uncontrolled diabetes. Recently, at the University of Tennessee Medical Center in Knoxville, we successfully treated an uncontrolled diabetic patient with rhinocerebral Mucormycosis as a sequela of his COVID-19 treatment.

Published by Elsevier Inc.

Publication types

Case Reports
Review

MeSH terms

COVID-19 Drug Treatment*
Diabetes Mellitus*
Humans
Mucormycosis* / drug therapy
SARS-CoV-2